



Abgenix to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

FREMONT, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Abgenix, Inc. (Nasdaq: ABGX) today announced that it will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Thursday, February 10, 2005 at 7:30 a.m. PT / 10:30 a.m. ET. The presentation will be webcast live and may be accessed by visiting the Abgenix website at www.abgenix.com. A replay of the webcast will also be available on the company's website until Thursday, February 24, 2005.

Bill Ringo, president and chief executive officer of Abgenix, will provide an update on the company's antibody drug development activities.

About Abgenix

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at www.abgenix.com.

SOURCE Abgenix, Inc.
02/03/2005

CONTACT: Ami Knoefler, Director, Corporate Communications, of Abgenix, Inc., +1-510-284-6350, or +1-510-284-6605

Web site: <http://www.abgenix.com>